Community-acquired Bacterial Pneumonia
Infectious Diseases
2
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Zai LabOmadacycline
PfizerCeftaroline
Clinical Trials (2)
Total enrollment: 948 patients across 2 trials
A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin for Treating Adult Subjects With CABP
Start: Nov 2023Est. completion: Nov 2025100 patients
Phase 3Recruiting
A Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia
Start: Dec 2011Est. completion: May 2013848 patients
Phase 3Completed
Related Jobs in Infectious Diseases
Senior Recruiter
Invivyd
New Haven, CT (Northeast preferred)
7h ago
$120K - $160K/yr
Senior Associate Scientist (contract), Upstream Polysaccharide Process Development
VaxCyte
San Carlos, California, United States
10h ago
$56/hr
Senior Associate Scientist (contract), Polysaccharide Analytical Development
VaxCyte
San Carlos, California, United States
10h ago
$56/hr
Director, Program Management
Metaphore Biotechnologies
Somerville, MA USA
13h ago
$179K - $237K/yr
Technician, Operations, DSP/ Technicien(ne) des opérations, DSP
Verona Pharma
CAN - Prince Edward Island - Charlottetown
Yesterday
$47K - $79K/yr
HVAC Maintenance Technician
Verona Pharma
USA - Delaware - Millsboro (Intervet)
Yesterday
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 948 patients
2 companies competing in this space